Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274(26):18438–18445. https://doi.org/10.1074/jbc.274.26.18438

CAS  Article  PubMed  Google Scholar 

Soderling SH, Bayuga SJ, Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 96(12):7071–7076. https://doi.org/10.1073/pnas.96.12.7071

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kelly MP (2018) Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cell Signal 42:281–291. https://doi.org/10.1016/j.cellsig.2017.11.004

CAS  Article  PubMed  Google Scholar 

Cardinale A, Fusco FR (2018) Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington’s disease. CNS Neurosci Ther 24(4):319–328. https://doi.org/10.1111/cns.12834

CAS  Article  PubMed  PubMed Central  Google Scholar 

Persson J, Szalisznyo K, Antoni G, Wall A, Fallmar D, Zora H, Boden R (2020) Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study. Eur Arch Psychiatry Clin Neurosci 270(4):451–459. https://doi.org/10.1007/s00406-019-01021-0

Article  PubMed  Google Scholar 

Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139(2):597–607. https://doi.org/10.1016/j.neuroscience.2005.12.042

CAS  Article  PubMed  Google Scholar 

Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985(2):113–126. https://doi.org/10.1016/s0006-8993(03)02754-9

CAS  Article  PubMed  Google Scholar 

Hebb AL, Robertson HA, Denovan-Wright EM (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123(4):967–981. https://doi.org/10.1016/j.neuroscience.2003.11.009

CAS  Article  PubMed  Google Scholar 

Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS ONE 5(10):e13417. https://doi.org/10.1371/journal.pone.0013417

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lee YY, Park JS, Leem YH, Park JE, Kim DY, Choi YH, Park EM, Kang JL, Kim HS (2019) The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson’s disease mouse models. J Neuroinflammation 16(1):246. https://doi.org/10.1186/s12974-019-1649-3

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ito M, Aswendt M, Lee AG, Ishizaka S, Cao Z, Wang EH, Levy SL, Smerin DL, McNab JA, Zeineh M, Leuze C, Goubran M, Cheng MY, Steinberg GK (2018) RNA-sequencing analysis revealed a distinct motor cortex transcriptome in spontaneously recovered mice after stroke. Stroke 49(9):2191–2199. https://doi.org/10.1161/STROKEAHA.118.021508

CAS  Article  PubMed  PubMed Central  Google Scholar 

Birjandi SZ, Abduljawad N, Nair S, Dehghani M, Suzuki K, Kimura H, Carmichael ST (2021) Phosphodiesterase 10A inhibition leads to brain region-specific recovery based on stroke type. Transl Stroke Res 12(2):303–315. https://doi.org/10.1007/s12975-020-00819-8

CAS  Article  PubMed  Google Scholar 

Suzuki K, Harada A, Suzuki H, Miyamoto M, Kimura H (2016) TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 41(9):2252–2262. https://doi.org/10.1038/npp.2016.20

CAS  Article  Google Scholar 

Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA (2017) A Randomized multiple dose pharmacokinetic study of a novel PDE10A inhibitor TAK-063 in subjects with stable schizophrenia and Japanese subjects and modeling of exposure relationships to adverse events. Drugs R D 17(4):631–643. https://doi.org/10.1007/s40268-017-0214-8

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yurgelun-Todd DA, Renshaw PF, Goldsmith P, Uz T, Macek TA (2019) A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects. Psychopharmacology. https://doi.org/10.1007/s00213-019-05366-1

Article  PubMed  PubMed Central  Google Scholar 

Harada A, Suzuki K, Kamiguchi N, Miyamoto M, Tohyama K, Nakashima K, Taniguchi T, Kimura H (2015) Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS ONE 10(3):e0122197. https://doi.org/10.1371/journal.pone.0122197

CAS  Article  PubMed  PubMed Central  Google Scholar 

Suzuki K, Kimura H (2018) TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. CNS Neurosci Ther 24(7):604–614. https://doi.org/10.1111/cns.12798

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kunitomo J, Yoshikawa M, Fushimi M, Kawada A, Quinn JF, Oki H, Kokubo H, Kondo M, Nakashima K, Kamiguchi N, Suzuki K, Kimura H, Taniguchi T (2014) Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyri dazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. J Med Chem 57(22):9627–9643. https://doi.org/10.1021/jm5013648

CAS  Article  PubMed  Google Scholar 

Beker MC, Caglayan AB, Kelestemur T, Caglayan B, Yalcin E, Yulug B, Kilic U, Hermann DM, Kilic E (2015) Effects of normobaric oxygen and melatonin on reperfusion injury: role of cerebral microcirculation. Oncotarget 6(31):30604–30614. https://doi.org/10.18632/oncotarget.5773

Article  PubMed  PubMed Central  Google Scholar 

Caglayan AB, Beker MC, Caglayan B, Yalcin E, Caglayan A, Yulug B, Hanoglu L, Kutlu S, Doeppner TR, Hermann DM, Kilic E (2019) Acute and post-acute neuromodulation induces stroke recovery by promoting survival signaling, neurogenesis, and pyramidal tract plasticity. Front Cell Neurosci 13:144. https://doi.org/10.3389/fncel.2019.00144

CAS  Article  PubMed  PubMed Central  Google Scholar 

Beker MC, Caglayan B, Caglayan AB, Kelestemur T, Yalcin E, Caglayan A, Kilic U, Baykal AT, Reiter RJ, Kilic E (2019) Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway components and cellular survival. Sci Rep 9(1):19082. https://doi.org/10.1038/s41598-019-55663-0

CAS  Article  PubMed  PubMed Central  Google Scholar 

Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359–362. https://doi.org/10.1038/nmeth.1322

CAS  Article  PubMed  Google Scholar 

Yalcin E, Beker MC, Turkseven S, Caglayan B, Gurel B, Kilic U, Caglayan AB, Kalkan R, Baykal AT, Kelestemur T, Kilic E (2019) Evidence that melatonin downregulates Nedd4-1 E3 ligase and its role in cellular survival. Toxicol Appl Pharmacol 379:114686. https://doi.org/10.1016/j.taap.2019.114686

CAS  Article  PubMed  Google Scholar 

Beker MC, Caglayan B, Yalcin E, Caglayan AB, Turkseven S, Gurel B, Kelestemur T, Sertel E, Sahin Z, Kutlu S, Kilic U, Baykal AT, Kilic E (2018) Time-of-Day dependent neuronal injury after ischemic stroke: implication of circadian clock transcriptional factor Bmal1 and survival kinase AKT. Mol Neurobiol 55(3):2565–2576. https://doi.org/10.1007/s12035-017-0524-4

CAS  Article  PubMed  Google Scholar 

Acioglu C, Mirabelli E, Baykal AT, Ni L, Ratnayake A, Heary RF, Elkabes S (2016) Toll like receptor 9 antagonism modulates spinal cord neuronal function and survival: direct versus astrocyte-mediated mechanisms. Brain Behav Immun 56:310–324. https://doi.org/10.1016/j.bbi.2016.03.027

CAS  Article  PubMed  Google Scholar 

Kilic E, Bahr M, Hermann DM (2001) Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 32(11):2641–2647. https://doi.org/10.1161/hs1101.097381

CAS  Article  PubMed  Google Scholar 

Bacigaluppi M, Pluchino S, Peruzzotti-Jametti L, Kilic E, Kilic U, Salani G, Brambilla E, West MJ, Comi G, Martino G, Hermann DM (2009) Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain 132(Pt 8):2239–2251. https://doi.org/10.1093/brain/awp174

Article  PubMed  Google Scholar 

Huan X, Oumei C, Hongmei Q, Junxia Y, Xiaojiao M, Qingsong J (2019) PDE9 inhibition promotes proliferation of neural stem cells via cGMP-PKG pathway following oxygen-glucose deprivation/reoxygenation injury in vitro. Neurochem Int 133:104630. https://doi.org/10.1016/j.neuint.2019.104630

CAS  Article  PubMed  Google Scholar 

Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100(3):309–327. https://doi.org/10.1161/01.RES.0000256354.95791.f1

CAS  Article  PubMed  Google Scholar 

Russwurm C, Koesling D, Russwurm M (2015) Phosphodiesterase 10A is tethered to a synaptic signaling complex in striatum. J Biol Chem 290(19):11936–11947. https://doi.org/10.1074/jbc.M114.595769

CAS  Article  PubMed  PubMed Central  Google Scholar 

Tejeda GS, Whiteley EL, Deeb TZ, Burli RW, Moss SJ, Sheridan E, Brandon NJ, Baillie GS (2020) Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme. Proc Natl Acad Sci USA 117(1):677–688. https://doi.org/10.1073/pnas.1916398117

CAS  Article  PubMed  Google Scholar 

Knopp C, Hausler M, Muller B, Damen R, Stoppe A, Mull M, Elbracht M, Kurth I, Begemann M (2019) PDE10A mutation in two sisters with a hyperkinetic movement disorder—response to levodopa. Parkinsonism Relat Disord 63:240–242. https://doi.org/10.1016/j.parkreldis.2019.02.007

CAS  Article  PubMed  Google Scholar